NCT04528082 (BEAN) is a Phase 3 clinical trial of Apremilast in Behçet Disease, sponsored by Amgen.

Who is sponsoring NCT04528082?

NCT04528082 is sponsored by Amgen.

What drugs are being tested in NCT04528082?

Interventions in NCT04528082: Apremilast, Placebo.

What condition does NCT04528082 study?

NCT04528082 studies Behçet Disease.

Is NCT04528082 still recruiting?

NCT04528082 is currently recruiting now. Last updated 1 December 2025.

Last reviewed 2025-12-01 · How we verify

NCT04528082: BEAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

Recruiting now Phase 3 Last updated 1 December 2025

What this trial tests

Phase 3 trial testing Apremilast in Behçet Disease in 60 participants. Currently enrolling.

Timeline

9 September 2021

Primary endpoint
7 February 2030

17 December 2030

Quick facts

Lead sponsor	Amgen
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	9 September 2021
Primary completion	7 February 2030
Estimated completion	17 December 2030
Sites	27 locations across France, Italy, Greece, United Kingdom, Israel, Switzerland, Turkey (Türkiye), Spain

Drugs / interventions tested

Apremilast (APREMILAST) — full drug profile →
Placebo

Conditions studied

Behçet Disease — all drugs for Behçet Disease →

Sponsor

Amgen — full company profile →

Who can join

Adults 2 to 17, any sex, with Behçet Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.
Carmona-Rocha E, Rusiñol L, Puig L. · · 2025 · cited 11× · PMID 39861739 · DOI 10.3390/pharmaceutics17010091
Treatment Options in Pediatric Behçet's Disease.
Giani T, Luppino AF, Ferrara G. · · 2023 · cited 10× · PMID 36626047 · DOI 10.1007/s40272-022-00548-5

Verify or expand the search:

Other trials of Apremilast

Trials testing the same drug.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07432386 — Methotrexate Versus Apremilast for Pruritus in Psoriasis · Phase 4 · not yet recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07337434 — To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Present · EARLY_PHASE1 · recruiting

Other recruiting trials for Behçet Disease

Currently open trials in the same condition.

NCT06451575 — Thrombophilia and Thrombosis in Behçet's Disease · recruiting
NCT05879419 — Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases · Phase 4 · active not recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04528082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 1 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04528082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing